Mosaic ImmunoEngineering (OTCMKTS:CPMV) Issues Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) released its earnings results on Tuesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports.

Mosaic ImmunoEngineering Stock Performance

Shares of CPMV stock remained flat at $0.54 on Tuesday. The stock had a trading volume of 52 shares, compared to its average volume of 969. The firm has a market capitalization of $3.91 million, a PE ratio of -3.60 and a beta of 0.11. The stock’s 50 day simple moving average is $0.71 and its 200-day simple moving average is $0.84. Mosaic ImmunoEngineering has a one year low of $0.10 and a one year high of $1.13.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.